Iqvia and Veeva Form Global Partnership, Settle Legal Disputes

Iqvia and Veeva have announced a global partnership and resolved their legal disputes. The partnership allows customers to use software, data, and services from both companies together, with agreements on master data and software access. Iqvia has also joined Veeva's CRO Clinical Data Partner program, enabling the use of Veeva Clinical Suite for clinical trials. The partnership aims to provide customers with a seamless experience across both companies' offerings.

Veeva Systems (NYSE: VEEV) and IQVIA (NYSE: IQV) have announced a comprehensive global partnership that encompasses both clinical and commercial domains. The agreement, which also resolves all pending legal disputes between the two companies, allows for seamless integration of their software, data, technology, and services. This strategic move aims to provide customers with a unified and efficient experience across both companies' offerings.

The partnership includes master data and third-party access agreements, enabling mutual data usage across platforms such as Veeva Network, Veeva Nitro, and Veeva AI. IQVIA has joined multiple Veeva partner programs to support customer integrations. In the clinical domain, IQVIA's participation in Veeva's CRO Clinical Data Partner program will facilitate clinical trials execution using Veeva's software products, particularly in EDC (Electronic Data Capture) implementations. This integration will accelerate database builds, study locks, and data delivery, addressing major pain points in clinical development timelines.

The resolution of legal disputes and establishment of these partnerships create significant operational and commercial value for both companies. For Veeva, this removes a competitive obstacle and expands the utility of its software platforms. For IQVIA, it opens access to a significant software customer base and enhances the value proposition of its data and services. The elimination of uncertainty and potential financial liabilities further benefits both companies.

The partnership spans two critical domains: commercial operations and clinical trials. On the commercial side, master data and third-party access agreements allow for crucial data interoperability, with IQVIA's industry-leading data now accessible within Veeva's Network, Nitro, and AI applications. Simultaneously, Veeva's data becomes available within IQVIA's commercial ecosystem. On the clinical side, IQVIA joining Veeva's CRO Clinical Data Partner program enables the use of Veeva's Clinical Suite for trial execution, including the critical EDC system.

This strategic development represents a significant shift for both companies, ending a contentious relationship marked by legal disputes. The partnership eliminates significant friction for life sciences companies that previously had to navigate complex technical and legal barriers when attempting to use both companies' solutions together. By joining each other's partner programs and establishing master agreements, they've created a streamlined process for third-party access approvals, addressing a major operational headache for their clients.

For Veeva, this removes a competitive obstacle and expands their software platforms' utility. For IQVIA, it opens access to a significant software customer base and enhances the value proposition of their data and services. The resolution of legal disputes also eliminates uncertainty and potential financial liabilities for both companies.

References
[1] https://www.stocktitan.net/news/VEEV/iqvia-and-veeva-announce-long-term-clinical-and-commercial-wfu78yarscmn.html
[2] https://www.marketwatch.com/story/iqvia-teams-with-veeva-systems-after-resolving-legal-dispute-c3bad76d